Why ovarian cancer treatment and survival differ
Identifying Multilevel Drivers of Differences in Ovarian Cancer Treatment and Survival: An Integrative Approach
['FUNDING_R01'] · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · NIH-11169765
This project looks at medical care, neighborhood, and tumor factors that might explain why some women with epithelial ovarian cancer get different treatments and have different survival.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH (nih funded) |
| Locations | 1 site (SALT LAKE CITY, UNITED STATES) |
| Trial ID | NIH-11169765 on ClinicalTrials.gov |
What this research studies
From a patient's perspective, this work combines medical records, tumor tissue, and neighborhood information from over 6,000 women with epithelial ovarian cancer treated within Kaiser Permanente Northern California between 2000 and 2022. Pathology samples will be centrally reviewed using current WHO criteria and detailed chart reviews will capture care and treatment details not available in electronic records. The team will analyze neighborhood, health‑system, patient, and tumor factors to see how they relate to treatment received, recurrence, and survival. In a subgroup of 800 women with high‑grade serous tumors they will also study tumor gene expression subtypes to connect biology with treatment patterns and outcomes.
Who could benefit from this research
Good fit: Ideal candidates are women diagnosed with epithelial ovarian cancer—particularly high‑grade serous cases—who were treated within Kaiser Permanente Northern California during 2000–2022 or who can share their medical records and tumor samples with the study team.
Not a fit: People without epithelial ovarian cancer (including men or those with non‑epithelial ovarian tumors) or patients treated entirely outside the study health system are unlikely to receive direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could identify who is at risk for receiving suboptimal ovarian cancer care and inform changes in care delivery or policy to improve survival.
How similar studies have performed: Previous studies have shown that treatment access and tumor biology affect ovarian cancer outcomes, but combining biology, neighborhood, and health‑system data in a single large cohort is a novel approach.
Where this research is happening
SALT LAKE CITY, UNITED STATES
- UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH — SALT LAKE CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DOHERTY, JENNIFER ANNE — UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH
- Study coordinator: DOHERTY, JENNIFER ANNE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology, Cancer Patient